Davita Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.22 (market cap $18.25B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and iShares iBoxx $ High Yield Corporate Bond ETF for 59 Days on average.
| DVA | HYG | |
|---|---|---|
Market Cap | $11.28B | $18.25B |
Volume | 650,294 | 59,233,080 |
Sector | Health | Fixed Income |
52-Week High | $240.96 | $81.28 |
52-Week Low | $103.87 | $76.90 |
Typical Hold Time | 113 Days | 59 Days |
Enterprise Value | $24.00B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
HYG trades at $77.18, down 0.12% with a bearish technical signal from moving averages. The ETF shows neutral oscillators but faces pressure from rising Treasury yields, with the 10-year hitting 2007 highs. Recent dividend payments of $0.34-$0.44 provide income support, but bond market volatility remains a headwind as high-yield corporate debt costs increase.
Outlook remains cautious given the bearish technical setup and rising rate environment. Income investors may find value in HYG's dividend yield, but further bond market selloffs could pressure prices. Key risks include Fed policy uncertainty and corporate credit quality deterioration in a higher rate environment.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →